These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. A case of primary meningeal melanocytosis treated with combination therapy with nivolumab and ipilimumab. Akatsuka T; Toyama T; Morimura S; Komuta M; Mori I; Tanaka T; Tabei Y; Kawashima M; Matsuno A; Sugaya M J Dermatol; 2023 Apr; 50(4):e125-e126. PubMed ID: 36440954 [No Abstract] [Full Text] [Related]
31. Combination immune checkpoint blockade with ipilimumab and nivolumab in the management of advanced melanoma. Spain L; Larkin J Expert Opin Biol Ther; 2016; 16(3):389-96. PubMed ID: 26750801 [TBL] [Abstract][Full Text] [Related]
32. Ipilimumab Combined with Nivolumab: A Standard of Care for the Treatment of Advanced Melanoma? Carlino MS; Long GV Clin Cancer Res; 2016 Aug; 22(16):3992-8. PubMed ID: 27340279 [TBL] [Abstract][Full Text] [Related]
33. The new paradigm of systemic therapies for metastatic melanoma. Volpe VO; Klufas DM; Hegde U; Grant-Kels JM J Am Acad Dermatol; 2017 Aug; 77(2):356-368. PubMed ID: 28711086 [TBL] [Abstract][Full Text] [Related]
34. Myocarditis as an immune-related adverse event with ipilimumab/nivolumab combination therapy for metastatic melanoma. Mehta A; Gupta A; Hannallah F; Koshy T; Reimold S Melanoma Res; 2016 Jun; 26(3):319-20. PubMed ID: 27110676 [No Abstract] [Full Text] [Related]
35. Immune Check Point Inhibitors Combination in Melanoma: Worth the Toxicity? Orloff M; Weight R; Valsecchi ME; Sato T Rev Recent Clin Trials; 2016; 11(2):81-6. PubMed ID: 27028970 [TBL] [Abstract][Full Text] [Related]
36. Combined use of nivolumab and ipilimumab in Japanese patients with melanoma: a multicentre retrospective study of 111 cases. Fujisawa Y; Namikawa K; Yoshino K; Kiniwa Y; Ito T; Kato H; Matsushita S; Hoashi T; Nakamura Y; Yoshikawa S; Miyagawa T; Asai J; Matsuya T; Fukushima S; Kato J; Takenouchi T; Uchi H; Masuzawa M; Yanagi T; Maekawa T Br J Dermatol; 2023 Jul; 189(2):223-250. PubMed ID: 37017027 [No Abstract] [Full Text] [Related]
37. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Di Giacomo AM; Ascierto PA; Pilla L; Santinami M; Ferrucci PF; Giannarelli D; Marasco A; Rivoltini L; Simeone E; Nicoletti SV; Fonsatti E; Annesi D; Queirolo P; Testori A; Ridolfi R; Parmiani G; Maio M Lancet Oncol; 2012 Sep; 13(9):879-86. PubMed ID: 22894884 [TBL] [Abstract][Full Text] [Related]
38. A Cost-Effectiveness Analysis of Nivolumab Compared with Ipilimumab for the Treatment of BRAF Wild-Type Advanced Melanoma in Australia. Bohensky MA; Pasupathi K; Gorelik A; Kim H; Harrison JP; Liew D Value Health; 2016 Dec; 19(8):1009-1015. PubMed ID: 27987627 [TBL] [Abstract][Full Text] [Related]
39. The dynamics of medical care in skin cancers. Dummer R Curr Opin Oncol; 2018 Mar; 30(2):105-106. PubMed ID: 29303788 [No Abstract] [Full Text] [Related]